Calendrier des promotions NeuBase Therapeutics, Inc.
Calendrier avancé
Graphique simple
À propos de l'entreprise
NeuBase Therapeutics, Inc., a preclinical-stage biopharmaceutical company, focuses on the development of therapies to treat rare genetic diseases and cancers caused by mutant genes. The company's proprietary modular peptide-nucleic acid antisense oligo (PATrOL) platform focuses on addressing Huntington's disease (HD) and myotonic dystrophy, as well as other genetic disorders, and cancer and oncology applications. Its pipeline includes NT0100 for Huntington's disease; NT0200 for myotonic dystrophy type 1; and NT0300 treatment targets the mutated KRAS gene. Plus de détailsEBITDA | -0.0031 |
---|---|
EV/EBITDA | -2.17 |
IPO date | 2007-05-01 |
ISIN | US64132K1025 |
Industry | Biotechnology |
P/BV | 0.9603 |
Sector | Health Care |
Валюта | usd |
Валюта отчета | usd |
Сайт | https://www.neubasetherapeutics.com |
Цена ао | 0.4788 |
Changement de prix par jour: | -0% (0.378) |
---|---|
Changement de prix par semaine: | -0% (0.378) |
Changement de prix par mois: | -0% (0.378) |
Changement de prix sur 3 mois: | -0% (0.378) |
Changement de prix sur six mois: | -15.72% (0.4485) |
Changement de prix par an: | -53.28% (0.809) |
Evolution du prix sur 3 ans: | -90.36% (3.92) |
Evolution du prix sur 5 ans: | -91.8% (4.61) |
Evolution des prix depuis le début de l'année: | -48.92% (0.74) |
|
Sous-estimation
|
Efficacité
|
|||||||||||||||||||||||||||||||||||||
Dividendes
|
Devoir
|
Impulsion de croissance
|
Établissements | Volume | Partager, % |
---|---|---|
Greenlight Capital, Inc. | 136350 | 3.63 |
UBS Group AG | 65724 | 1.75 |
Point72 Asset Management, L.P. | 62500 | 1.67 |
Renaissance Technologies, LLC | 56967 | 1.52 |
Carnegie Mellon University | 46970 | 1.25 |
Two Sigma Investments, LP | 21083 | 0.56 |
Vanguard Group Inc | 18981 | 0.51 |
Kestra Advisory Services, LLC | 16476 | 0.44 |
Jacob Asset Management Of New York LLC | 15655 | 0.42 |
Prelude Capital Management LLC | 15550 | 0.41 |
Superviseur | Titre d'emploi | Paiement | Année de naissance |
---|---|---|---|
Dr. Dietrich A. Stephan Ph.D. | Founder, President & Director | 836.58k | 1970 (54 année) |
Mr. Todd P. Branning | Interim CEO, CFO & Secretary | 427.44k | 1970 (54 année) |
Adresse: United States, Pittsburgh. PA, 350 Technology Drive - ouvrir dans Google Maps, ouvrir les cartes Yandex
Site web: https://www.neubasetherapeutics.com
Site web: https://www.neubasetherapeutics.com